Quarterly & Annual Financial Results
Zydus Lifesciences Reports Strong FY26 Performance; Revenue Up 17%, Buyback and Dividend Announced
NSE
zyduslife
BSE
532321
Zydus Lifesciences reported strong FY26 financial performance with revenue growth of 17% YoY and EBITDA growth of 20% YoY. The company also announced a ₹1,100 crore buyback at ₹1,150 per share and recommended a 100% dividend for FY26.
PRICE-SENSITIVE TRIGGER
Event: Q4 FY26 and Full Year FY26 Financial Results Announcement
Type: Share Buyback / Capital Return
Impact: Positive
Immediate Effect: Strong revenue growth, margin expansion, improved profitability, and shareholder-friendly actions such as dividend and buyback are likely to strengthen investor sentiment.
Key Metrics:
- FY26 Revenue: ₹2,71,484 million (+16.8% YoY)
- FY26 EBITDA: ₹84,751 million (+20.1% YoY)
- FY26 EBITDA Margin: 31.2%
- FY26 Net Profit: ₹54,564 million (+15.0% YoY)
- Q4 FY26 Revenue: ₹75,870 million (+16.2% YoY)
- Q4 FY26 EBITDA: ₹25,544 million (+20.2% YoY)
- Q4 FY26 Net Profit: ₹15,929 million (+14.6% YoY)
- Buyback Size: ₹11,000 million
- Buyback Price: ₹1,150 per share
- Dividend Recommendation: 100% for FY26
Highlight Metric:
- FY26 EBITDA rose 20.1% YoY to ₹84,751 million with EBITDA margin improving to 31.2%.
What Happened ?
Zydus Lifesciences announced its audited Q4 and FY26 financial results, reporting strong growth across revenue, EBITDA, and profitability metrics.
The Board approved a share buyback worth up to ₹11,000 million at ₹1,150 per share, representing a 16% premium to the previous closing price, and also recommended a 100% dividend for FY26.
The company delivered broad-based growth across India formulations, international markets, consumer wellness, and MedTech businesses, while continuing investments in R&D, biologics, specialty products, and innovation pipeline expansion.
Key Details
Financial Performance:
- Q4 FY26 revenue increased 16.2% YoY to ₹75,870 million.
- Q4 EBITDA grew 20.2% YoY to ₹25,544 million.
- EBITDA margin improved by 110 basis points to 33.7%.
- FY26 net profit increased 15% YoY to ₹54,564 million.
- Organic capex for FY26 stood at ₹17,145 million.
Segment Performance:
- India formulations revenue rose 14% YoY in Q4.
- International formulations business grew 45% YoY.
- Consumer wellness business surged 61% YoY in Q4.
- MedTech business reported revenues of ₹3,275 million.
- North America formulations business declined 6% YoY but improved sequentially.
Product & Innovation Updates:
- Launched world’s first biosimilar of Nivolumab under Tishtha™.
- Introduced biosimilar Aflibercept under Anyra™.
- Launched Semaglutide injection under multiple brands.
- Received USFDA orphan drug designation for Desidustat in sickle cell disease.
- Initiated multiple Phase III and Phase I biologics trials.
Strategic & Corporate Actions:
- Approved ₹11,000 million share buyback.
- Recommended 100% dividend for FY26.
- Signed agreement to acquire US-based Assertio Holdings for US$166 million to strengthen specialty business presence in the US market.
Note:
- Management highlighted that the company’s strong balance sheet provides flexibility for future investments, acquisitions, and pipeline expansion initiatives.
Risk Analysis
Key Risks:
- North America formulations business declined YoY.
- One-time litigation settlement expenses impacted profitability adjustments.
- Integration risk related to Assertio Holdings acquisition.
- High R&D intensity may pressure near-term margins.
- Regulatory approvals and clinical trial outcomes remain critical.
Worst Case Scenario:
- Any delay in specialty product commercialization, adverse USFDA observations, or acquisition integration issues could affect profitability growth and investor sentiment.
Risk Level: Medium
Company Commentary
- Management stated FY26 closed on a strong note with delivery on both revenue growth and profitability.
- Zydus highlighted confidence in its future growth pipeline and innovation portfolio.
- The company reiterated focus on acquisition integration, quality standards, and synergy realization.
- Dr. Sharvil Patel stated that the strong balance sheet enables continued investments and business strengthening initiatives.
Official Exchange Filing: Zydus Lifesciences Limited